Lixte Biotechnology Holdings, Inc.
NASDAQ Capital MarketTotal Valuation
Lixte Biotechnology Holdings, Inc. carries a market capitalization of 83.09M, placing it among publicly traded companies globally.
| Market Cap | 83.09M |
| Enterprise Value | N/A |
Share Statistics
Lixte Biotechnology Holdings, Inc. currently has 11.62M shares outstanding.
| Shares Outstanding | 11.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.34 |
| P/TBV Ratio | 2.21 |
| P/FCF Ratio | -4.67 |
| P/OCF Ratio | -4.67 |
Financial Position
Lixte Biotechnology Holdings, Inc. maintains a current ratio of 2.78, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.78 |
| Quick Ratio | 2.65 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -700.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -116.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lixte Biotechnology Holdings, Inc.'s stock has gained approximately 382.73381% over the past 52 weeks. The 50-day moving average sits at 4.14, while the 200-day moving average is 4.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | 382.73381% |
| 50-Day Moving Average | 4.14 |
| 200-Day Moving Average | 4.01 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -6.39M, while operating income came in at -6.39M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -6.39M |
| Pretax Income | -7.29M |
| Net Income | -7.22M |
| EBITDA | -6.39M |
| EBIT | -6.39M |
| Earnings Per Share (EPS) | -1.11 |
Balance Sheet
Total book value stands at -60.00M, with working capital of 2.18M providing operational flexibility.
| Cash & Cash Equivalents | 3.25M |
| Total Debt | N/A |
| Net Debt | -3.25M |
| Equity (Book Value) | -60.00M |
| Book Value Per Share | -9.10 |
| Working Capital | 2.18M |
Cash Flow
Lixte Biotechnology Holdings, Inc. produced -4.33M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.33M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.33M |
| FCF Per Share | -0.66 |
Dividends & Yields
The company's payout ratio of 1.17 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 1.17 |
| Shareholder Yield | -46.42 |
| FCF Yield | -21.41 |
Stock Splits
Lixte Biotechnology Holdings, Inc.'s most recent stock split took place on June 5, 2023 with a 10:1 split ratio.
| Last Split Date | 6/5/2023 |
| Split Ratio | 10:1 |
Scores
Lixte Biotechnology Holdings, Inc. posts an Altman Z-Score of -2.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.23 |